Dbv Technologies Equity 2024

Dbv Technologies Aktienanalyse

What does Dbv Technologies do?

DBV Technologies SA (DBV) is a biopharmaceutical company specializing in the development of therapies for allergic diseases. The company was founded in 2002 by Pierre-Henri Benhamou in France. Its objective is to set new standards in the treatment of allergies through innovative approaches. DBV's business model is based on the research and development of products based on epicutaneous tests (application of allergens on the skin). This alternative method to the common oral immunotherapy (OIT) treats allergic reactions using special patch products. These patches contain the allergens that trigger an allergic reaction in the patient. Through continuous contact with the allergens, the body's defense mechanisms learn that there is no threat and suppress the allergic reaction. DBV offers two products based on epicutaneous tests: Viaskin Peanut and Viaskin Milk. Viaskin Peanut is DBV's first product for the treatment of peanut allergies, while Viaskin Milk is the next product in the pipeline. Viaskin Peanut is a patch that contains a microdose of peanut protein. It is applied to the patient's skin, gradually familiarizing the immune system with the allergen and reducing allergic reactions. The patch can also be used in children, making it an important innovation in the treatment of peanut allergies. Viaskin Milk is also a patch that contains specific proteins found in milk. This patch aims to revolutionize the treatment of milk intolerances, as there are currently no specific therapies for this type of allergy. Again, this is an epicutaneous test. DBV has previously entered into several partnerships with other companies. This includes a collaboration with Nestle to further expand the potential of epicutaneous test products. Networking with insurers and health insurance companies is also an important strategic step in establishing the use of epicutaneous test products in practice. The company is particularly active in Europe and the USA. Its IPO took place in 2012. In 2017, DBV became the first French drug manufacturer to receive approval from the European Medicines Agency (EMA) for Viaskin Peanut. DBV Technologies SA has great potential in the development of epicutaneous products for long-term treatment of allergies. The company has achieved promising results in a short period of time and has established itself as an innovative player in the field of allergology. Dbv Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Dbv Technologies's Equity

Dbv Technologies's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Dbv Technologies's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Dbv Technologies's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Dbv Technologies's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Dbv Technologies’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Dbv Technologies Stock

What is the equity of Dbv Technologies this year?

Dbv Technologies has equity of 140.33 M USD this year.

What was the equity of Dbv Technologies compared to the previous year?

The equity of Dbv Technologies has increased/decreased by -27.85% decreased compared to the previous year.

What impact does a high equity have on investors of Dbv Technologies?

A high equity is advantageous for investors of Dbv Technologies as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Dbv Technologies?

A low equity can be a risk for investors of Dbv Technologies, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Dbv Technologies affect the company?

An increase in equity of Dbv Technologies can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Dbv Technologies affect the company?

A reduction in equity of Dbv Technologies can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Dbv Technologies?

Some factors that can affect the equity of Dbv Technologies include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Dbv Technologies so important for investors?

The equity of Dbv Technologies is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Dbv Technologies take to change the equity?

To change equity, Dbv Technologies can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Dbv Technologies pay?

Over the past 12 months, Dbv Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dbv Technologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Dbv Technologies?

The current dividend yield of Dbv Technologies is .

When does Dbv Technologies pay dividends?

Dbv Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Dbv Technologies?

Dbv Technologies paid dividends every year for the past 0 years.

What is the dividend of Dbv Technologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Dbv Technologies located?

Dbv Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dbv Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dbv Technologies from 6/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/20/2024.

When did Dbv Technologies pay the last dividend?

The last dividend was paid out on 6/20/2024.

What was the dividend of Dbv Technologies in the year 2023?

In the year 2023, Dbv Technologies distributed 0 USD as dividends.

In which currency does Dbv Technologies pay out the dividend?

The dividends of Dbv Technologies are distributed in USD.